Exelixis, Inc.

États‑Unis d’Amérique


 
Quantité totale PI 394
Quantité totale incluant filiales 395 (+ 1 pour les filiales)
Rang # Quantité totale PI 3 269
Note d'activité PI 3,1/5.0    183
Rang # Activité PI 3 755
Symbole boursier
ISIN US30161Q1040
Capitalisation 10,000M  (USD)
Industrie Biotechnology
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

131 14
61 9
165 4
10
 
Dernier brevet 2025 - Malate salt of n-(4-{[6,7-bis(me...
Premier brevet 1998 - Nucleic acids and proteins of c....
Dernière marque 2019 - PREVAIL OVER CANCER
Première marque 1999 - EXELIXIS

Filiales

1 subsidiaries with IP (1 patents, 0 trademarks)

 S'inscrire grtuitement pour accéder à la liste des filiales

Industrie (Classification de Nice)

Derniers inventions, produits et services

2024 Invention Malate salt of n-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropan...
Invention Processes for preparing quinoline compounds and pharmaceutical compositions containing such compo...
Invention Ilt2 binding agents and uses thereof. e.g.e.g., antibodies, including monospecific and multispeci...
Invention Anti-ror antibody constructs. Anti-ROR antibody constructs, pharmaceutical compositions comprisi...
Invention Interleukin-13 receptor subunit alpha-2 binding agents and uses thereof. e.ge.g, antibodies, incl...
Invention Activatable tyrosine-protein kinase membrane receptor (ror) antibody-drug conjugates and uses the...
Invention Interleukin-13 receptor subunit alpha-2 antibody-drug conjugates and uses thereof. The present di...
Invention Tyrosine-protein kinase membrane receptor 1 (ror1) antibody-drug conjugates and uses thereof. The...
Invention Activatable ror binding agents and uses thereof. The present disclosure provides activatable ROR ...
Invention Fused pyrazole derivatives as usp1 inhibitors. The present disclosure provides fused pyrazole der...
Invention Method of treating cancer and bone cancer pain. This invention is directed to the treatment of c...
Invention Liquid dosage forms to treat cancer. This invention relates to a liquid pharmaceutical compositi...
Invention Crystalline forms and salt forms of a kinase inhibitor. The present invention relates to crystal...
Invention Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane...
Invention Amhrii antibody-drug conjugates and uses thereof. The present disclosure provides AMHRII antibody...
Invention Dll3 antibody-drug conjugates and uses thereof. The present disclosure provides DLL3 antibody-dru...
Invention Nkg2a binding agents and uses thereof. The present disclosure provides NKG2A binding agents (e.g,...
Invention Method of treating cancer. This invention is directed to the treatment of cancer, particularly c...
2023 Invention Compounds that inhibit pkmyt1. Disclosed herein are compounds according to Formula (I). Compounds...
Invention Compounds that inhibit pkmyt1. Disclosed herein are compounds according to Formula I. (I). Compou...
Invention C-met modulator pharmaceutical compositions. Pharmaceutical compositions and unit dosage forms c...
Invention C]pyridine compounds and derivatives as usp1 inhibitors. Hcc]pyridine compounds of formula (I), w...
Invention Triple negative breast cancer treatment method. Disclosed is a method of treating triple negativ...
Invention Tissue factor antibody-drug conjugates and uses thereof. The present disclosure provides anti-tis...
Invention Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cycl...
Invention Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n’-(4-f...
Invention Agents that bind to nkg2a and pd-l1 and uses thereof. e.g.e.g., multispecific antibodies such as ...
Invention Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophe...
Invention Compounds for the treatment of kinase-dependent disorders. Disclosed herein are compounds of Form...
Invention Heterocyclic adenosine receptor antagonists. Heterocyclic compounds useful as antagonists of ade...
Invention Cancer therapy using a combination of a cdk7 inhibitor with an oral serd. The present invention p...
Invention 5t4 antibody-drug conjugates and uses thereof. The present disclosure provides 5T4 antibody-drug ...
Invention 5t4 binding agents and uses thereof. The present disclosure provides 5T4 binding agents (e.g., an...
Invention Compounds for the treatment of kinase-dependent disorders. Disclosed herein are compounds of For...
Invention Methods of treating solid tumors with anti-tissue factor antibody-drug conjugates. Provided herei...
Invention Method of treating cancer. This invention is directed to the treatment of cancer, particularly ca...
Invention Multispecific binding agents and uses thereof. The present disclosure provides multispecific bind...
2022 Invention Compounds for the treatment of kinase-dependent disorders. Disclosed herein are compounds of for...
Invention Compounds for the treatment of kinase-dependent disorders. The present disclosure relates to tyr...
Invention Liquid dosage forms to treat cancer. This invention relates to a liquid pharmaceutical compositio...
Invention Pyridone compounds and methods of use. The present disclosure relates generally to compounds and...
2021 Invention Pharmaceutical compositions of a kinase inhibitor. The present invention relates to pharmaceutic...
Invention Method of treating cancer. This invention is directed to the treatment of cancer, particularly s...
Invention Multispecific binding agents and uses thereof. The present disclosure provides multispecific bin...
Invention Cd47 binding agents and uses thereof. The present disclosure provides CD47 binding agents (e.g.,...
Invention Pd-l1 binding agents and uses thereof. The present disclosure provides PD-L1 binding agents (e.g...
Invention Combinations for the treatment of cancer. The present invention relates to combinations comprisi...
2020 Invention Amh-competitive antagonist antibody. The present invention relates to a competitive antagonist a...
2019 P/S Online information services, namely, providing scientific research information related to oncolog...
2018 P/S Pharmaceutical preparations for the treatment of cancer, pain, infection, inflammation, hormone d...
2017 P/S Business administration of patient reimbursement programs in order to assist patients in obtainin...
P/S Pharmaceutical research and development services
P/S Pharmaceutical preparations for the treatment of cancer, pain, infection, inflammation, hormone ...
2016 P/S Pharmaceutical preparations for the treatment of cancer, pain, hormone disorders in the field of ...
2014 P/S Pharmaceutical preparations for the treatment of cancer, pain, disorders of the endocrine system,...
P/S Pharmaceutical preparations; chemical, analytical and diagnostic reagents for in vivo use; analge...
2012 P/S Pharmaceutical preparations for the treatment of cancer, pain, infection, inflammation, disorders...
P/S Chemicals and biochemicals for use in science, research and for laboratory use; chemical, analyti...
2009 P/S Pharmaceutical research and development services.
P/S Pharmaceutical preparations for the treatment of cancer. Pharmaceutical research and development ...
2008 P/S pharmaceutical research and development services
2002 P/S Chemicals used in industry, science and photography, as well as in agriculture, horticulture and ...
P/S Pharmaceutical preparations for the treatment of cancer.
2001 P/S pharmaceutical preparations for the treatment of cancer
1999 P/S Books, pamphlets and brochures featuring information on research and development in the field of ...